Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Metabolism, Inborn Errors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hemoglobinopathies 1Disease Progression 1Congenital Bone Marrow Failure Syndromes 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1Adenocarcinoma 1

Interventions

pembrolizumab 8Cetuximab 8Cisplatin 6Fluorouracil 5Paclitaxel 4durvalumab 3Radiotherapy 3Leucovorin 3Docetaxel 3Carboplatin 3tremelimumab 2niraparib 2avelumab 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Nivolumab 2Ipilimumab 2Bevacizumab 2zalutumumab 1yeast-CEA vaccine 1spartalizumab 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1regorafenib 1penpulimab 1paclitaxel poliglumex 1osimertinib 1necitumumab 1dostarlimab 1demplatin pegraglumer 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Squamous Cell × Clinical Trials, Phase I as Topic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡